Active surveillance provides a unique opportunity to study biomarkers of prostate cancer behaviour, although only small volumes of tumor tissue are typically available. We have evaluated a technique for constructing tissue microarrays (TMAs) from needle biopsies for assessing immunohistochemical markers in localized prostate cancer managed by active surveillance. TMAs were constructed from diagnostic prostate biopsies for 60 patients with localized prostatic adenocarcinoma in a prospective cohort study of active surveillance. Radical treatment was recommended for a prostate-specific antigen (PSA) velocity greater than 1 ng ml À1 per year or adverse histology in repeat biopsies, defined as Gleason score X4 þ 3 or 450% of cores involved. Sections from the TMAs were stained with H&E, P63/AMACR and Ki-67. Time to radical treatment was analysed with respect to clinical characteristics and Ki-67 LI. At a median follow up of 36 months, 25/60 (42%) patients had received radical treatment. On univariate analysis, PSA density (P ¼ 0.001), Gleason score (P ¼ 0.001), clinical T stage (P ¼ 0.01), Ki-67 LI (P ¼ 0.02) and initial PSA (P ¼ 0.04) were associated with time to radical treatment. On multivariate analysis, PSA density (P ¼ 0.01), Ki-67 LI (P ¼ 0.03) and Gleason score (P ¼ 0.04) were independent determinants of progression to radical treatment. TMAs constructed from prostate needle biopsies can be used to assess immunohistochemical markers in localized prostate cancer managed by active surveillance. Ki-67 LI merits further study as a possible biomarker of early prostate cancer behaviour.
Introduction
Treatment options for localized prostate cancer are many and varied, ranging from immediate radical surgery through to observation alone. Radical prostatectomy has been shown to have an overall survival advantage compared with watchful waiting. 1 Nonetheless, a proportion of prostate cancers can behave in an indolent fashion even without treatment, with no effect either on health or longevity. 2 Identifying those patients with clinically relevant cancers who may benefit from radical treatment remains a significant challenge.
Active surveillance, first described by Choo et al., 3, 4 is an approach to the management of localised prostate cancer that aims to avoid overtreatment of men with indolent cancers, whereas still providing treatment with radical intent within a window of curability for those who need it. 5 In contrast to traditional watchful waiting, a policy of observation with the use of palliative treatment for symptomatic progression, active surveillance consists of close monitoring with radical treatment recommended on the basis of prostate-specific antigen (PSA) kinetics or the detection of adverse histology in repeat biopsies. However, active surveillance has two important limitations: first, approximately 40% of men who embark on active surveillance will subsequently proceed to deferred radical treatment, and it is currently unknown whether this delay will adversely affect treatment efficacy. Second, living with untreated prostate cancer, not knowing whether treatment will be required may impose a psychological burden. For both these reasons, it would be ideal to have markers, available at the time of diagnosis, which would predict the need for treatment. Patients at high risk of disease progression could then receive immediate, rather than deferred, radical treatment, whereas those truly at low risk of disease progression could be observed with greater confidence.
Active surveillance provides a unique opportunity to study biomarkers of early prostate cancer behaviour. 6 However, the prostate tissue available is limited to needle biopsy specimens, which often contain only a small proportion of cancer tissue. These biopsies are not suitable for constructing conventional tissue microarrays (TMAs) for high throughput testing of molecular markers. 7 We have previously described a 'checkerboard' technique for constructing TMAs from needle biopsy specimens. 8 To date, the biopsy TMA technique has not been applied to the small volume cancers managed by active surveillance.
The Ki-67 antigen is a nuclear protein expressed in nearly all phases of the cell cycle and this expression, quantified immunohistochemically in cancer cells as the Ki-67 labelling index (Ki-67 LI), provides an estimate of the growth fraction of cancers. 9, 10 Evidence for the predictive role of Ki-67 LI in determining prostate cancer outcomes has been established for men that are treated radically. [11] [12] [13] [14] [15] [16] [17] [18] In most studies, Ki-67 LI has been evaluated on cancer tissue obtained from transurethral resection (TURP) or radical prostatectomy specimens, although two of the studies used pre-treatment needle biopsies taken from patients who subsequently received radiotherapy. 14, 18 The prognostic role of Ki-67 LI has also been established for prostate cancer-specific survival in patients managed by watchful waiting. 19, 20 Importantly however, none of these studies were targeted at men with low-risk localized disease who are suitable for management by active surveillance. In addition, the techniques used to evaluate Ki-67 LI in all of these studies were not suitable for analysis of multiple markers in a high-throughput fashion.
In this study, we aimed to validate the utility of our 'checkerboard' biopsy TMA technique for examining immunohistochemical markers in prostate cancer patients managed by active surveillance, through an investigation of the prognostic value of Ki-67 LI.
Materials and methods

Clinical samples
Men with untreated, localized (clinical stage T1/2a, Gleason score p3 þ 4; PSA o15; p50% positive cores) prostate cancer were managed in a prospective study of active surveillance at the Royal Marsden Hospital NHS Foundation Trust. The protocol included a PSA blood test at 3-month intervals, and a repeat transrectal ultrasound guided prostate biopsy 18-24 months after diagnosis. Both the initial diagnostic and the repeat prostate biopsy specimens were subject to central histopathological review. Radical treatment was recommended in the event of a PSA velocity greater than 1 ng ml À1 per year or adverse features on repeat biopsy defined as Gleason score X4 þ 3 or 450% of cores involved. Clinical and pathological data were prospectively recorded in a trial-specific database. At the time of analysis, 326 patients had been recruited to this study. This study had ethical approval from the Royal Marsden loco-regional ethics committee, and all patients gave their informed consent.
Initially, diagnostic needle biopsies were used in the construction of 'checkerboard' TMAs from a series of 60 patients in the active surveillance study. These patients were selected by (1) the availability of paraffin blocks from the diagnostic biopsies, (2) the amount and condition of residual tissue in the paraffin blocks and (3) the availability of follow-up data from 18 to 24 months repeat biopsy. Twenty of the patients were selected (by CCP) by virtue of adverse histology in their repeat biopsies, to ensure a greater number of events for analysis. CCP was not involved in the construction of the TMAs or the immunohistochemical analysis of Ki-67 LI. All other authors were blinded to the repeat biopsy results. For each patient, cancerous regions from between 1 and 5 biopsy cores of the diagnostic samples were assembled on a biopsy TMA as described previously. 8 All patients consented for their pathological specimens to be used for research.
p63/AMACR
Sections (3 mm) from the TMAs were cut and picked up on Superfrost charged glass slides. Sections were dewaxed and antigen retrieval was performed using epitope retrieval solution 2 (pH 9.0) for 20 min at 100 1C on a Bond maX immunostainer (Vision BioSystems, UK). Primary antibody (p63 1/200 þ AMACR 1/100) was applied for 20 min and then visualized using the bond Polymer Refine Detection System (DS9800; Vision BioSystems). Both primary antibodies were from Dako: p63 (catalogue no. M7247) and AMACR (catalogue no. M3616).
Ki-67
Sections (3 mm) from the TMAs were cut and picked up on Superfrost charged glass slides. Slides were barcoded and placed in Ventana Benchmark XT immunohistochemistry stainer, which performs de-waxing followed by antigen retrieval (for 30 min) and subsequently antibody incubation (37 1C for 40 min) and detection (run time approximately 3.5 h). Antibody used was Dako MIB1 clone, mouse monoclonal anti-human antibody for the Ki-67 antigen (Dako catalogue no. M7240); dilution 1:100. Following completion of staining run, slides were removed from machine and washed in mild neutral detergent to remove 'liquid cover slip', a protective layer put onto slides by the machine. Slides were counterstained for 30 s with Mayer's Haemalum, and then washed for 1-2 min before dehydration, clearing and mounting. Slides were then reviewed along with control section to ascertain staining result. Ki-67 positivity was assessed manually, and defined as the presence of nuclear staining for the MIB-1 antibody in the cancer cells. Ki-67 LI was defined as the proportion of cancer nuclei positive for Ki-67 staining relative to the total number of cancer nuclei counted. The maximum level of staining detected in any single cancer core was taken as the Ki-67 LI for each patient. Ki-67 scoring was performed by two authors, SJ and GK (a specialist uropathologist), without prior knowledge of the clinical outcome on these patients. Diagnosis of cancer was made using adjacent sections stained for H&E and p63/ AMACR.
Statistical analysis
The primary outcome variable was time to radical treatment. The relationship between the primary 
Results
Patient characteristics
Biopsy TMAs were constructed from diagnostic needle biopsies for 60 men. Their clinical characteristics are shown in Table 1 . After a median follow-up of 36 months (range 16-81 months), 25 (42%) patients had received radical treatment. Of these 25 patients, 22 (88%) had adverse histology on their repeat biopsies. A PSA velocity greater than 1 ng ml À1 per year was the indication for radical treatment in the other three patients.
Ki-67 immunohistochemistry results
Using the maximum level of staining in any single cancer core as Ki-67 LI for each patient, the median Ki-67 LI was 1 (range 0-8.75) for the entire cohort. Patients were stratified into two groups based on this cut-off value of 1 for Kaplan-Meier analysis of association between Ki-67 LI and time to radical treatment. The distribution of Ki-67 LI is illustrated in Figure 1 . An example of Ki-67 staining is shown in Figure 2 . Of the 25 patients who received radical treatment, 15, 4 and 6 had a maximum Ki-67 LI 41, 1 and o1, respectively. Of the 35 patients who did not receive radical treatment, 11, 7 and 24 had a maximum Ki-67 LI of 41, 1 and p1, respectively.
Analysis of time to radical treatment
Factors significantly associated with time to radical treatment, using univariate logistic regression analysis were: PSA density (P ¼ 0.001), Gleason score (P ¼ 0.001), clinical T stage (P ¼ 0.01), Ki-67 LI (P ¼ 0.02) and initial PSA (P ¼ 0.04) (see Table 2 ). The Kaplan-Meier plot shown in Figure 3 illustrates the association between Ki-67 LI (using the cut-off value of one patients were stratified into two groups: Ki-67 LI41 vs Ki-67 LIp1) and time to radical treatment. On multivariate Cox proportional hazards regression analysis, PSA density (P ¼ 0.01), maximum Ki-67 LI (P ¼ 0.03) and Gleason score (P ¼ 0.04) were significant independent determinants of time to radical treatment ( Table 2 ).
Discussion
Needle biopsies that have already been used for diagnostic purposes are unsuitable for the conventional TMA construction method for high-throughput analysis of multiple markers. 7 This study provides validation of the 'checkerboard' biopsy TMA technique 8 by demonstrating the feasibility of analysing an established predictive marker, Ki-67 LI, on TMAs constructed from diagnostic biopsies from patients with untreated, localized prostate cancer managed by active surveillance. The cases in this study had low-or intermediate-risk disease, and most had p20% maximum involvement by cancer in any single core of their diagnostic biopsies. We were able to take multiple sections from these biopsy TMAs and stain separate sections with H&E, p63/ AMACR and Ki-67. In principle, the remaining sections from the 'checkerboard' biopsy TMAs could be used to test multiple additional tissue markers.
The association we observed between Ki-67 LI and prostate cancer outcome is consistent with previous studies in other patient groups. A significant association of Ki-67 LI with outcome of radical treatment has been Biopsy TMA technique S Jhavar et al demonstrated in several studies. 14, 17, 18, 21 In addition, two studies have examined the prognostic utility of Ki-67 LI in prostate cancer patients managed conservatively. 20, 22 Both demonstrated a significant association between Ki-67 LI and prostate cancer disease-free survival. However, these studies included patients with high-risk disease, assessed Ki-67 LI on TURP tissue, and did not include analysis of baseline PSA levels.
The association observed between Ki-67 LI in diagnostic biopsy specimens and time to radical treatment raises the possibility that Ki-67 LI could be useful, in combination with established clinical characteristics, to predict the natural history of low-risk prostate cancer. However, given that only 60 patients were included, and the criteria used to initiate radical treatment are to some extent arbitrary, this possibility needs further evaluation.
In summary, the results from this study provide validation of the biopsy TMA approach and demonstrate that (i) TMAs constructed from prostate needle biopsies can be used to assess immunohistochemical markers in localized prostate cancer managed by active surveillance and (ii) that Ki-67 merits further study as a possible biomarker of prostate cancer behaviour. 
